Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.
Antibodies
COVID-19
Development
Omicron
SARS-CoV-2
Therapy
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
20
12
2021
revised:
29
04
2022
accepted:
03
05
2022
pubmed:
10
5
2022
medline:
11
6
2022
entrez:
9
5
2022
Statut:
ppublish
Résumé
Antibodies against SARS-CoV-2 are important to generate protective immunity, with convalescent plasma one of the first therapies approved. An alternative source of polyclonal antibodies suitable for upscaling would be more amendable to regulatory approval and widespread use. In this study, sheep were immunised with SARS-CoV-2 whole spike protein or one of the subunit proteins: S1 and S2. Once substantial antibody titres were generated, plasma was collected and samples pooled for each antigen. Non-specific antibodies were removed via affinity-purification to yield candidate products for testing in a hamster model of SARS-CoV-2 infection. Affinity-purified polyclonal antibodies to whole spike, S1 and S2 proteins were evaluated for in vitro for neutralising activity against SARS-CoV-2 Wuhan-like virus (Australia/VIC01/2020) and a recent variant of concern, B.1.1.529 BA.1 (Omicron), antibody-binding, complement fixation and phagocytosis assays were also performed. All antibody preparations demonstrated an effect against SARS-CoV-2 disease in the hamster model of challenge, with those raised against the S2 subunit providing the most promise. A rapid, cost-effective therapy for COVID-19 was developed which provides a source of highly active immunoglobulin specific to SARS-CoV-2 with multi-functional activity.
Identifiants
pubmed: 35533779
pii: S0166-3542(22)00101-2
doi: 10.1016/j.antiviral.2022.105332
pmc: PMC9075985
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105332Subventions
Organisme : Medical Research Council
ID : MC_PC_19077
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Crown Copyright © 2022. Published by Elsevier B.V. All rights reserved.
Références
Sci Rep. 2016 Jul 28;6:30497
pubmed: 27465308
Medicina (B Aires). 2020;80 Suppl 3:1-6
pubmed: 32658841
Sci Immunol. 2020 Jun 11;5(48):
pubmed: 32527802
Cell. 2020 Oct 29;183(3):730-738.e13
pubmed: 32979942
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Life Sci. 2021 May 1;272:119245
pubmed: 33609539
Inflamm Allergy Drug Targets. 2011 Oct;10(5):369-80
pubmed: 21745181
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Science. 2005 Sep 16;309(5742):1864-8
pubmed: 16166518
Drug Discov Today. 2006 Jul;11(13-14):655-60
pubmed: 16793535
Cell. 2020 Sep 3;182(5):1284-1294.e9
pubmed: 32730807
Nat Protoc. 2021 Jun;16(6):3114-3140
pubmed: 33893470
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Elife. 2020 Oct 28;9:
pubmed: 33112236
Med J Aust. 2020 Jun;212(10):459-462
pubmed: 32237278
Methods Mol Biol. 2022;2414:341-362
pubmed: 34784045
Int J Biol Sci. 2021 Apr 10;17(6):1486-1496
pubmed: 33907512
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
FEBS Lett. 2006 Oct 16;580(24):5612-20
pubmed: 16989815
Comp Immunol Microbiol Infect Dis. 2005 May;28(3):167-76
pubmed: 15857656
Expert Rev Vaccines. 2022 Jul;21(7):877-884
pubmed: 34015243
J Infect Dis. 2016 Apr 1;213(7):1124-33
pubmed: 26715676
Int J Infect Dis. 2020 Nov;100:483-489
pubmed: 32920233
Antiviral Res. 2013 Feb;97(2):108-11
pubmed: 23165089
Comp Immunol Microbiol Infect Dis. 2009 Jan;32(1):9-19
pubmed: 18242705
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
Viruses. 2012 Jun;4(6):1011-33
pubmed: 22816037
Front Immunol. 2017 Nov 20;8:1590
pubmed: 29209323
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
Monoclon Antib Immunodiagn Immunother. 2021 Apr;40(2):36-49
pubmed: 33900819
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Clin Vaccine Immunol. 2014 Aug;21(8):1023-36
pubmed: 24920599
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102
pubmed: 32258207
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Cochrane Database Syst Rev. 2020 Jul 10;7:CD013600
pubmed: 32648959
Transfusion. 2021 Apr;61(4):1313-1323
pubmed: 33586160
J Immunol Methods. 2012 Dec 14;386(1-2):117-23
pubmed: 23023091
J Clin Microbiol. 2019 Dec 23;58(1):
pubmed: 31666364
Viruses. 2021 Nov 09;13(11):
pubmed: 34835057
Trials. 2021 Mar 9;22(1):199
pubmed: 33750432
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
Sci Rep. 2017 Jun 22;7(1):4099
pubmed: 28642489
Nat Med. 2021 Feb;27(2):205-211
pubmed: 33469205
Nature. 2020 May;581(7807):215-220
pubmed: 32225176